Boston Scientific
BSXGlobal medical technology leader transforming treatment for complex conditions across cardiology, endoscopy, urology, and neuromodulation.
FDA ClearedCE MarkS&P 500
$94.20
+3.1%
Market Data
Headquarters
Marlborough, MA
CEO
Michael Mahoney
Founded
1979
Employees
48,000+
Sector
Interventional MedTech
Therapeutic Area
Cardiology, Endoscopy, Neuromodulation
Stage
Public
Total Funding
Public (NYSE: BSX)
Regulatory Pipeline
FARAPULSE PFA System
PMA · Class III · Jan 2024
WATCHMAN FLX Pro LAAC
PMA · Class III · Oct 2023
Funding History
IPO
1992
$45M
NYSE
Clinical Trials
FARAPULSE IDE
CompletedPhase III · US, EU
Open Positions
Electrophysiology R&D Lead
Cardiology · Marlborough, MA
$160K-$200K+ RSUs
EPPFACatheter Design